Lanreotide

Active ingredient: Lanreotide Acetate

In short: Lanreotide injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option. The goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth

Forms & strengthsInjection: 120 mg/0.5 mL sterile, single-dose, pre-filled syringe fitted with an automatic needle guard (fitted with a 20 mm needle covered by a plastic cap). The pre-filled syringe contains a white to pale yellow, semi-solid formulation.
LabelAmneal Pharmaceuticals LLC
Label updatedSep 25, 2026

What is Lanreotide used for?

Lanreotide injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.

The goal of treatment in acromegaly is to reduce growth hormone (GH) and insulin growth factor-1 (IGF-1) levels to normal.

Lanreotide injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.

Lanreotide injection is indicated for the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.

Lanreotide dosage

For deep subcutaneous injection only.

Lanreotide injection is intended for administration by a healthcare provider.

Refer to the Instructions For Use (IFU) for complete administration instructions with illustrations.

Preparation

Remove lanreotide injection from the refrigerator 30 minutes prior to administration and allow to come to room temperature.

Keep pouch sealed until just prior to injection.

Product left in its sealed pouch at room temperature (not to exceed 104°F or 40°C) for up to 72 hours may be returned to the refrigerator for continued storage and use at a later time.

Prior to administration, inspect the lanreotide injection syringe visually for particulate matter and discoloration. Do not administer if particulate matter or discoloration is observed. The content of the pre-filled syringe is a semi-solid phase having a gel-like appearance, with viscous characteristics and a color varying from white to pale yellow. The supersaturated solution can also contain micro bubbles that can clear up during injection. These differences are normal and do not interfere with the quality of the product.

Administration

1. Slowly administer for 20 seconds as a deep subcutaneous injection in the superior external quadrant of the buttock.

2. Alternate the injection site between the right and left sides from one injection to the next.

3. Discard unused portion.

Acromegaly

The recommended starting dosage of lanreotide injection is 90 mg given via the deep subcutaneous route, at 4-week intervals for 3 months.

After 3 months, the dosage may be adjusted as follows:

GH greater than 1 ng/mL to less than or equal to 2.5 ng/mL, IGF-1 normal, and clinical symptoms controlled: maintain lanreotide injection dosage at 90 mg every 4 weeks.

GH greater than 2.5 ng/mL, IGF-1 elevated, and/or clinical symptoms uncontrolled: increase lanreotide injection dosage to 120 mg every 4 weeks.

GH less than or equal to 1 ng/mL, IGF-1 normal, and clinical symptoms controlled: reduce lanreotide injection dosage to 60 mg every 4 weeks.

Thereafter, the dosage should be adjusted according to the response of the patient as judged by a reduction in serum GH and/or IGF-1 levels; and/or changes in symptoms of acromegaly.

Patients who are controlled on lanreotide injection 60 mg or 90 mg may be considered for an extended dosing interval of lanreotide injection 120 mg every 6 or 8 weeks. GH and IGF-1 levels should be obtained 6 weeks after this change in dosing regimen to evaluate persistence of patient response.

Continued monitoring of patient response with dosage adjustments for biochemical and clinical symptom control, as necessary, is recommended. …

How to take Lanreotide — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hypersensitivity Reactions

Advise patients to immediately contact their healthcare provider if they experience serious hypersensitivity reactions, such as angioedema or anaphylaxis .

Cholelithiasis and Complications of Cholelithiasis

Advise patients to contact their healthcare provider if they experience signs or symptoms of gallstones (cholelithiasis) or complications of gallstones (e.g., cholecystitis, cholangitis, or pancreatitis) .

Hyperglycemia and Hypoglycemia

Advise patients to immediately contact their healthcare provider if they experience signs or symptoms of hyper- or hypoglycemia .

Cardiovascular Abnormalities

Advise patients to immediately contact their healthcare provider if they experience bradycardia .

Thyroid Function Abnormalities

Advise patients to contact their healthcare provider if they experience signs or symptoms of hypothyroidism .

Laboratory Tests

Advise patients with acromegaly that response to lanreotide injection should be monitored by periodic measurements of GH and IGF-1 levels, with a goal of decreasing these levels to the normal range . …

Warnings & precautions

Do not take this medicine if: Lanreotide injection is contraindicated in patients with history of a hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide .

Lanreotide injection may reduce gallbladder motility and lead to gallstone formation; therefore, patients may need to be monitored periodically . There have been post-marketing reports of cholelithiasis (gallstones) resulting in complications, including cholecystitis, cholangitis, and pancreatitis, and requiring cholecystectomy in patients taking lanreotide injection. If complications of cholelithiasis are suspected, discontinue lanreotide injection and treat appropriately.

Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. Hence, patients treated with lanreotide injection may experience hypoglycemia or hyperglycemia. Blood glucose levels should be monitored when lanreotide treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly .

The most common overall cardiac adverse reactions observed in three pooled lanreotide injection cardiac studies in patients with acromegaly were sinus bradycardia (12/217, 5.5%), bradycardia (6/217, 2.8%), and hypertension (12/217, 5.5%) .

In 81 patients with baseline heart rates of 60 beats per minute (bpm) or greater treated with lanreotide injection in Study 3, the incidence of heart rate less than 60 bpm was 23% (19/81) as compared to 16% (15/94) of placebo treated patients; 10 patients (12%) had documented heart rates less than 60 bpm on more than one visit. The incidence of documented episodes of heart rate less than 50 bpm as well as the incidence of bradycardia reported as an adverse event was 1% in each treatment group. …

Lanreotide side effects

The following adverse reactions to lanreotide injection are discussed in greater detail in other sections of the labeling:

Cholelithiasis and Complications of Cholelithiasis

Hyperglycemia and Hypoglycemia

Cardiovascular Abnormalities

Thyroid Function Abnormalities

Steatorrhea and Malabsorption of Dietary Fats

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Acromegaly

The data described below reflect exposure to lanreotide injection in 416 acromegalic patients in seven studies. One study was a fixed-dose pharmacokinetic study. The other six studies were open-label or extension studies, one had a placebo-controlled, run-in period, and another had an active control. The population was mainly Caucasian (329/353, 93%) with a median age of 53 years of age (range 19 years to 84 years). Fifty-four subjects (13%) were age 66 to 74 and 18 subjects (4.3%) were 75 years of age and older.

Patients were evenly matched for sex (205 males and 211 females). The median average monthly dose was 91.2 mg (e.g., 90 mg injected via the deep subcutaneous route every 4 weeks) over 385 days with a median cumulative dose of 1,290 mg. …

Drug interactions

Lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. Therefore, blood glucose levels should be monitored when lanreotide injection treatment is initiated or when the dose is altered, and antidiabetic treatment should be adjusted accordingly .

Concomitant administration of cyclosporine with lanreotide injection may decrease the absorption of cyclosporine, and therefore, may necessitate adjustment of cyclosporine dose to maintain therapeutic drug concentrations .

Limited published data indicate that concomitant administration of a somatostatin analog and bromocriptine may increase the absorption of bromocriptine .

Concomitant administration of bradycardia-inducing drugs (e.g., beta-blockers) may have an additive effect on the reduction of heart rate associated with lanreotide. Dosage adjustments of concomitant drugs may be necessary.

The limited published data available indicate that somatostatin analogs may decrease the metabolic clearance of compounds known to be metabolized by cytochrome P450 enzymes, which may be due to the suppression of growth hormone. …

About this medicine

Lanreotide Injection 120 mg/0.5 mL is a prolonged-release formulation for deep subcutaneous injection. It contains the drug substance lanreotide acetate, a synthetic octapeptide with a biological activity similar to naturally occurring somatostatin, water for injection and acetic acid (for pH adjustment).

Lanreotide Injection is available as sterile, ready-to-use, single-dose pre-filled syringes containing lanreotide acetate supersaturated bulk solution of 24.6% w/w lanreotide base.

Each syringe contains: | Lanreotide Injection,

120 mg/0.5 mL

Lanreotide acetate$ equivalent to lanreotide base | 120 mg

Acetic Acid (Glacial) 100% | q.s. to adjust pH

Water for injection | q.s. to 488 mg

Total Weight | 544 mg

$Lanreotide acetate contains 1 to 2 moles of the acetate.

Lanreotide acetate is a synthetic cyclical octapeptide analog of the natural hormone, somatostatin. Lanreotide acetate is chemically known as [cyclo S-S]-3-(2-naphthyl)-D-alanyl-L-cysteinyl-L-tyrosyl-D-tryptophyl-L-lysyl-L-valyl-L-cysteinyl-L-threoninamide, acetate salt. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID e240b3b9-7a07-46b5-bacc-04e915d4ebd4. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate